» Articles » PMID: 19100997

Gray Matter Atrophy Correlates with MS Disability Progression Measured with MSFC but Not EDSS

Overview
Journal J Neurol Sci
Publisher Elsevier
Specialty Neurology
Date 2008 Dec 23
PMID 19100997
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gray matter (GM) pathology is an important component of the multiple sclerosis (MS) disease process. Accelerated gray matter atrophy has been observed in MS patients, but its relationship to neurological disability is not defined. This study was done to determine the relationship between whole brain, GM, and white matter (WM) atrophy and MS disability progression.

Methods: Patients with MS and Clinically Isolated Syndromes (CIS), and age- and gender-matched healthy controls were entered into an observational protocol. Baseline brain parenchymal fraction (BPF), GM fraction, and WM fraction, and change over 4 years were correlated with sustained disability progression over the entire study duration. Disability progression was measured using the Multiple Sclerosis Functional Composite (MSFC) and the Expanded Disability Status Scale (EDSS).

Results: Seventy MS and CIS patients and 17 HCs were studied for an average of 6.6 years (range, 3.6-7.8 years). At the final visit, 7 patients were classified as CIS, 36 as relapsing-remitting MS (RRMS), and 27 as secondary progressive MS (SPMS). Baseline whole brain, GM, and WM atrophy predicted EDSS >6.0 at the last study visit. Twenty-one (33%) patients worsened using the EDSS to define disability progression; 29 (46%) worsened using MSFC to define disability progression. Patients with MSFC progression had significantly higher GM atrophy rates compared with patients who were stable on MSFC. White matter atrophy was similar in patients with and without disability progression. Atrophy rates were not different in patients with or without disability progression defined using EDSS.

Conclusions: Whole brain, GM, and WM atrophy predicted MS disability progression observed over the next 6.6 years. Gray matter atrophy rates over 4 years correlated with disability progression measured with the MSFC, but not EDSS. This indicates that MSFC defined disability progression is more closely linked to brain atrophy than EDSS defined disability progression, and provides important new insight into the poor correlation between MRI and clinical disability in MS. The findings confirm the clinical relevance of gray matter atrophy in MS.

Citing Articles

Neuroimaging markers and disability scales in multiple sclerosis: A systematic review and meta-analysis.

Mirmosayyeb O, Yazdan Panah M, Mokary Y, Mohammadi M, Moases Ghaffary E, Shaygannejad V PLoS One. 2024; 19(12):e0312421.

PMID: 39637162 PMC: 11620670. DOI: 10.1371/journal.pone.0312421.


Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.

Molenaar P, Noteboom S, van Nederpelt D, Krijnen E, Jelgerhuis J, Lam K J Neurol. 2024; 271(9):5958-5968.

PMID: 39008036 PMC: 11377687. DOI: 10.1007/s00415-024-12516-9.


Brain Atrophy and Physical and Cognitive Disability in Multiple Sclerosis.

Peno L, De Silanes De Miguel C, De Torres L, Ortiz M, Moreno M, Rodeno B Basic Clin Neurosci. 2023; 14(2):311-316.

PMID: 38107523 PMC: 10719973. DOI: 10.32598/bcn.2021.1893.1.


An Animal Model for Chronic Meningeal Inflammation and Inflammatory Demyelination of the Cerebral Cortex.

Enz L, Winkler A, Wrzos C, Dasen B, Nessler S, Stadelmann C Int J Mol Sci. 2023; 24(18).

PMID: 37762198 PMC: 10531364. DOI: 10.3390/ijms241813893.


Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.

Meijboom R, York E, Kampaite A, Harris M, White N, Valdes Hernandez M PLoS One. 2023; 18(7):e0288967.

PMID: 37506096 PMC: 10381059. DOI: 10.1371/journal.pone.0288967.


References
1.
Schwid S, Goodman A, Mattson D, Mihai C, Donohoe K, Petrie M . The measurement of ambulatory impairment in multiple sclerosis. Neurology. 1997; 49(5):1419-24. DOI: 10.1212/wnl.49.5.1419. View

2.
Rudick R, Fisher E, Lee J, Simon J, Jacobs L . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999; 53(8):1698-704. DOI: 10.1212/wnl.53.8.1698. View

3.
Nakamura K, Fisher E . Segmentation of brain magnetic resonance images for measurement of gray matter atrophy in multiple sclerosis patients. Neuroimage. 2008; 44(3):769-76. PMC: 3001325. DOI: 10.1016/j.neuroimage.2008.09.059. View

4.
Pirko I, Lucchinetti C, Sriram S, Bakshi R . Gray matter involvement in multiple sclerosis. Neurology. 2007; 68(9):634-42. DOI: 10.1212/01.wnl.0000250267.85698.7a. View

5.
Kutzelnigg A, Lassmann H . Cortical lesions and brain atrophy in MS. J Neurol Sci. 2005; 233(1-2):55-9. DOI: 10.1016/j.jns.2005.03.027. View